Apyx Medical Co. (NASDAQ:APYX) Sees Large Drop in Short Interest

Apyx Medical Co. (NASDAQ:APYX - Get Free Report) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 140,500 shares, a decrease of 39.0% from the October 31st total of 230,300 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average trading volume of 42,400 shares, the days-to-cover ratio is presently 3.3 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in APYX. RPg Family Wealth Advisory LLC acquired a new stake in Apyx Medical during the second quarter valued at approximately $101,000. Rathbones Group PLC boosted its stake in Apyx Medical by 148.0% in the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company's stock valued at $337,000 after buying an additional 150,000 shares in the last quarter. Private Advisor Group LLC boosted its stake in Apyx Medical by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 322,321 shares of the company's stock valued at $400,000 after buying an additional 12,180 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Apyx Medical by 2.9% during the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company's stock worth $685,000 after acquiring an additional 14,481 shares in the last quarter. Finally, Royce & Associates LP raised its stake in Apyx Medical by 3.4% during the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company's stock worth $3,202,000 after acquiring an additional 85,267 shares in the last quarter. Institutional investors and hedge funds own 55.33% of the company's stock.

Analyst Upgrades and Downgrades

APYX has been the topic of a number of research reports. JMP Securities reaffirmed a "market perform" rating on shares of Apyx Medical in a research report on Monday, September 16th. Craig Hallum raised shares of Apyx Medical to a "strong-buy" rating in a research report on Thursday, October 24th. Finally, BTIG Research initiated coverage on shares of Apyx Medical in a research note on Thursday, October 17th. They issued a "neutral" rating for the company.

Apyx Medical Stock Performance

Shares of APYX traded up $0.24 on Thursday, reaching $1.69. 142,036 shares of the stock traded hands, compared to its average volume of 81,010. The stock's 50-day moving average price is $1.25 and its 200-day moving average price is $1.32. The company has a debt-to-equity ratio of 3.03, a current ratio of 5.46 and a quick ratio of 4.52. The firm has a market cap of $63.62 million, a price-to-earnings ratio of -2.04 and a beta of 1.21. Apyx Medical has a 12 month low of $0.97 and a 12 month high of $3.26.

Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $11.49 million for the quarter, compared to analyst estimates of $11.66 million. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. During the same quarter in the previous year, the firm posted ($0.13) EPS. Equities analysts forecast that Apyx Medical will post -0.68 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.